Featured Research

from universities, journals, and other organizations

FDA Approves Drug For Use In Cataract Surgery

Date:
December 23, 2004
Source:
U.S. Food And Drug Administration
Summary:
The Food and Drug Administration (FDA) has announced the approval of Vision Blue (trypan blue ophthalmic solution). Vision Blue is the first product approved in the United States for staining the anterior lens capsule during cataract surgery.

The Food and Drug Administration (FDA) has announced the approval of Vision Blue (trypan blue ophthalmic solution). Vision Blue is the first product approved in the United States for staining the anterior lens capsule during cataract surgery.

Related Articles


The use of Vision Blue will enhance the ability of ophthalmologists (eye surgeons) to remove white cataracts, a very advanced mature cataract (typically seen in countries where medical care is not widely available), by allowing the ophthalmologist to see the capsule as it is cut and removed. Clean cuts in the capsule are known to reduce some of the risks associated with the surgical removal of a cataract. Over 1.4 million people have cataract surgery each year in the United States, although only a small portion of these cataracts are mature white cataracts.

A cataract is a clouding of the eye's naturally clear lens. Cataract development is a normal process of aging, but cataracts can also develop from eye injuries, certain diseases, such as diabetes, or medications. The lens focuses light rays on the retina -- the layer of light-sensing cells lining the back of the eye -- to produce a sharp image. When the lens becomes cloudy, light rays cannot pass through it easily, and vision is blurred. Surgery is the only way to remove a cataract. Selective staining of the anterior lens capsule with Vision Blue makes it easier to visualize, manipulate, and remove the cloudy lens through a surgical incision.

The safety and effectiveness of Vision Blue has been established in pediatric patients. No overall differences in safety and effectiveness have been observed between elderly and younger patients.

The adverse reactions from the use of Vision Blue are generally self-limited and of short duration. They include discoloration of intraocular lenses and staining of the posterior lens capsule and the vitreous.

Vision Blue is currently marketed in 30 countries. D.O.R.C. International of the Netherlands is the manufacturer.


Story Source:

The above story is based on materials provided by U.S. Food And Drug Administration. Note: Materials may be edited for content and length.


Cite This Page:

U.S. Food And Drug Administration. "FDA Approves Drug For Use In Cataract Surgery." ScienceDaily. ScienceDaily, 23 December 2004. <www.sciencedaily.com/releases/2004/12/041219133258.htm>.
U.S. Food And Drug Administration. (2004, December 23). FDA Approves Drug For Use In Cataract Surgery. ScienceDaily. Retrieved November 29, 2014 from www.sciencedaily.com/releases/2004/12/041219133258.htm
U.S. Food And Drug Administration. "FDA Approves Drug For Use In Cataract Surgery." ScienceDaily. www.sciencedaily.com/releases/2004/12/041219133258.htm (accessed November 29, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, November 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins